Etrasimod was effective and well tolerated as an induction and maintenance therapy
in patients with moderately to severely active ulcerative colitis. Etrasimod is a
treatment option with a unique combination of attributes that might address the persistent
unmet needs of patients with ulcerative colitis.
/PRNewswire/ The "Microbiome Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com s offering. The global Microbiome Therapeutics.